In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.
about
Key Challenges and Opportunities Associated with the Use of In Vitro Models to Detect Human DILI: Integrated Risk Assessment and Mitigation PlansMechanistic Modeling Reveals the Critical Knowledge Gaps in Bile Acid-Mediated DILIFusion of nonclinical and clinical data to predict human drug safety.Sandwich-Cultured Hepatocytes as a Tool to Study Drug Disposition and Drug-Induced Liver Injury.Human platelets as a platform to monitor metabolic biomarkers using stable isotopes and LC-MS.Idiosyncratic Drug-Induced Liver Injury (IDILI): Potential Mechanisms and Predictive Assays.High-content analysis/screening for predictive toxicology: application to hepatotoxicity and genotoxicity.Practical approaches to resolving reactive metabolite liabilities in early discovery.Detecting reactive drug metabolites for reducing the potential for drug toxicity.Metabolic activation and drug-induced liver injury: in vitro approaches for the safety risk assessment of new drugs.Current limitations and future opportunities for prediction of DILI from in vitro.Upgrading HepG2 cells with adenoviral vectors that encode drug-metabolizing enzymes: application for drug hepatotoxicity testing.Human biology-based drug safety evaluation: scientific rationale, current status and future challenges.The Promise of New Technologies to Reduce, Refine, or Replace Animal Use while Reducing Risks of Drug Induced Liver Injury in Pharmaceutical Development.Role of Multidrug Resistance Protein 3 in Antifungal-Induced Cholestasis.Immortalized Human Hepatic Cell Lines for In Vitro Testing and Research Purposes.Fasiglifam (TAK-875): Mechanistic Investigation and Retrospective Identification of Hazards for Drug Induced Liver Injury.A correlation between the in vitro drug toxicity of drugs to cell lines that express human P450s and their propensity to cause liver injury in humans.In vitro exploration of potential mechanisms of toxicity of the human hepatotoxic drug fenclozic acid.Test systems in drug discovery for hazard identification and risk assessment of human drug-induced liver injury.Quantifying and Communicating Uncertainty in Preclinical Human Dose-Prediction.Quantification of Drug-Induced Inhibition of Canalicular Cholyl-l-Lysyl-Fluorescein Excretion From Hepatocytes by High Content Cell Imaging.Setting Clinical Exposure Levels of Concern for Drug-Induced Liver Injury (DILI) Using Mechanistic in vitro Assays.Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury.A testing strategy to predict risk for drug-induced liver injury in humans using high-content screen assays and the 'rule-of-two' model.The Identification of Pivotal Transcriptional Factors Mediating Cell Responses To Drugs With Drug-Induced Liver Injury Liabilities.The metabolic fate of [14C]-fenclozic acid in the hepatic reductase null (HRN) mouse.Customised in vitro model to detect human metabolism-dependent idiosyncratic drug-induced liver injury.Synergistic Cytotoxicity from Drugs and Cytokines In Vitro as an Approach to Classify Drugs According to Their Potential to Cause Idiosyncratic Hepatotoxicity: A Proof-of-Concept Study.Characterization of human cytochrome P450 mediated bioactivation of amodiaquine and its major metabolite N-desethylamodiaquine.The synthesis of a tritium, carbon-14, and stable isotope-labeled cathepsin C inhibitors.The synthesis of tritium, carbon-14 and stable isotope labelled selective estrogen receptor degraders.A short expedient synthesis of [(14)C]Ticlopidine.A new twist to an old tale: novel insights into the differential toxicities of acetaminophen and its regioisomer N-acetyl-meta-aminophenol (AMAP).Current Concepts in Drug-Induced Bile Salt Export Pump (BSEP) Interference.Human Upcyte Hepatocytes: Characterization of the Hepatic Phenotype and Evaluation for Acute and Long-Term Hepatotoxicity Routine Testing.A multi-center preclinical study of gadoxetate DCE-MRI in rats as a biomarker of drug induced inhibition of liver transporter function.The metabolic fate of fenclozic acid in chimeric mice with a humanized liverCan BSEP Inhibition Testing In Drug Discovery And Development Reduce Liver Injury Risk? - An International Transporter Consortium PerspectiveImproved hepatic physiology in hepatic cytochrome P450 reductase null (HRN™) mice dosed orally with fenclozic acid
P2860
Q28075991-E13E398B-3E8E-47FF-89B4-A8B3AC9634BAQ33994553-8FA48A0B-5F45-4F03-AD39-592FA7AC9BE2Q34615323-19271C4E-A685-462D-B71D-481ED48391B1Q36972804-2F1B4775-66B1-4095-8C17-5D523B5D6A0AQ37551334-CD06B9EA-58D5-41ED-9945-2DA1F7EC2C0EQ37590883-8C0C1C11-D9CA-4C72-A0AD-15B3046A71CDQ38181625-9297FF38-95B7-4AFA-864D-D45798D4A88CQ38269781-5CD938B7-7A2F-4F81-BBC4-01EA6F4E0F9AQ38501264-E8A27DF8-9D32-4CA3-879E-A58271FF3504Q38675826-FF33160F-BD49-467F-BF5B-B7EFADE79807Q38739197-5A3976CF-C406-41D0-AE7B-E994792099AAQ38743580-CD3D7DFC-5ECE-4A14-A3D9-6845976471BBQ38763000-A4322775-ADD7-4EC7-8E47-EA3FADE4E1F9Q38774776-E20C0232-74C3-4350-9ED1-98C6A904039DQ38775583-4FE18490-C3D5-482E-9A8C-EEA9D790DA1BQ38843888-F169DC22-DA38-45E4-8F3F-3D31A5F962F4Q38958120-6E9C12A6-C0EB-4802-8DBF-AA5E27F0AA34Q39089080-FBB8E132-076B-4CDD-8FF4-74989A31ED64Q39162099-8D032E10-3CA0-451E-B467-F0C07805F083Q39366146-6BE1ED4B-F4BC-4025-A91A-9EA2B478F6DCQ40606599-86A0F5E7-1447-42E8-B4E4-EFA412A736E9Q40684311-5CB23F80-D18A-4A85-806B-9C509DEDA0ABQ40701934-E2F851DA-AA1C-49D0-947C-5C084649421AQ41051252-E7B6238F-8716-4DE0-BA52-C97CB268348EQ44367056-D8228400-3E99-442C-8BBA-40D7AA0FAE7DQ47652130-9B66FBC7-DDDA-4874-9D20-A6763B31323EQ48813784-71F0AF4C-9BC7-4677-A69A-1D4C97BB1095Q49219661-34C90957-5533-48B7-853A-0C2A220FBBD8Q50902309-02D448D9-B386-4504-945D-D94C30033CB4Q51414867-F5187F8E-883E-4629-912A-41A7AE6EEC5EQ51415832-43A163AB-6E47-4507-8223-E74BAA7185D8Q51552332-2658D6C4-6C26-4E2C-B16B-004CCEF6BF86Q51756241-21C062B9-8D88-49BA-8845-30990861D0F3Q51756765-B851A157-7472-4DDF-8044-B2D8D9612F51Q53085844-48665D34-A08B-4104-8660-3E76443EC8F5Q53085870-841B38E8-E7ED-41FB-97C5-0D8C10213D2FQ55408134-EF776D58-F6FE-4062-BAE2-82C65FBAFC44Q57109274-A7B36CDD-BA8E-48AD-B58E-D4CD2161DFADQ57111135-D4B7220D-5387-4F92-B093-D3321CA3BF8CQ57132848-C3CD5BCE-2D39-49AD-A975-52759AC7CCC0
P2860
In vitro approach to assess the potential for risk of idiosyncratic adverse reactions caused by candidate drugs.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
In vitro approach to assess th ...... ons caused by candidate drugs.
@en
In vitro approach to assess th ...... ons caused by candidate drugs.
@nl
type
label
In vitro approach to assess th ...... ons caused by candidate drugs.
@en
In vitro approach to assess th ...... ons caused by candidate drugs.
@nl
prefLabel
In vitro approach to assess th ...... ons caused by candidate drugs.
@en
In vitro approach to assess th ...... ons caused by candidate drugs.
@nl
P2093
P50
P356
P1476
In vitro approach to assess th ...... ions caused by candidate drugs
@en
P2093
Alison J Foster
Brian Middleton
Hugues Dolgos
Lars Weidolf
Richard A Thompson
Richard Weaver
Steve Swallow
P304
P356
10.1021/TX300091X
P577
2012-05-31T00:00:00Z